{
  "id": "fda_guidance_chunk_0319",
  "title": "Introduction - Part 319",
  "text": "report.34 248 However, there may not be complete information about corrective and preventative actions at the 249 time of closeout. Although there is no regulatory requirement for the inspected establishment to 250 respond to a Form FDA 483, a timely written response to the Form FDA 483 that includes 251 appropriate corrective and preventive actions could impact FDA’s determination of the need for 252 subsequent Agency action. FDA encourages establishments to provide written responses to the 253 observations within fifteen (15) U.S. business days after the end date of the inspection. 254 Responses submitted to FDA during that timeframe addressing the issues identified during the 255 inspection generally will be considered before further Agency action or decision. 29 See section 704(a)(5)(D) of the FD&C Act. 30 For additional detail on Form FDA 483, see Chapter 5 of the IOM. See also the Bioresearch Monitoring Program compliance programs. 31 Once the inspection is closed by the Agency, the inspected establishment will be provided a copy of the Establishment Inspection Report. See “FMD-145 -Release of the Establishment Inspection Report (EIR)” available at https://www.fda.gov/media/83055/download. 32 See “Reports of Observations” and “General Discussion with Management” under sections 5.5 and 5.7 of the IOM for more on discussing the objectionable conditions observed and the potential legal sanctions available to FDA after further review by the Agency. 33 Language on back of FDA Form 483. There may be other objectionable conditions that exist at the establishment that are not cited on the Form FDA 483. Also see the Bioresearch Monitoring Program compliance programs. 34 See “General Discussion with Management” under section 5.7 of the IOM. Contains Nonbinding Recommendations Draft — Not for Implementation 256 For domestic inspections, if the establishment chooses to respond in writing to the observations 257 discussed or listed on the Form FDA 483, the response should be addressed to the FDA OBIMO 258 division contact which is listed on the Form FDA 483. Hard copy responses may be mailed to 259 the address listed on the Form FDA 483 or emailed, with email being the preferred approach.35 It 260 is recommended that the respondent include the FDA Establishment Identification (FEI) of the 261 inspected location in its correspondence.36 For foreign inspections, if the establishment chooses 262 to respond in writing to the observations discussed or listed",
  "source": "FDA_clinical_trial_guidance.txt",
  "section_heading": "Introduction",
  "start_pos": 427392,
  "end_pos": 428928,
  "tokens": 512,
  "tags": [
    "efficacy",
    "regulatory",
    "data"
  ],
  "jurisdiction": "US",
  "document_type": "fda_guidance",
  "guidance_section": "general_guidance",
  "regulatory_weight": "recommendation",
  "created_at": "2025-10-23T02:25:44.700Z"
}